Cerebrospinal Fluid Treatment Platform

Our mission for the Minnetronix Cerebrospinal Fluid (CSF) Treatment Platform is to develop a safe, device-based alternative for treating neurodegenerative and life-threatening diseases that involve foreign bodies in the cerebrospinal fluid.

The Challenge

Subarachnoid hemorrhage (SAH) is a serious, life-threatening event caused by a ruptured aneurysm (bleeding into the space surrounding the brain).  Treatment focuses on stopping the bleeding, restoring normal blood flow, relieving the pressure on the brain, and preventing cerebral vasospasm. 1

Cerebral vasospasm is a common complication that may occur in SAH patients. It is a narrowing of cerebral arteries which reduces blood flow to regions of the brain.  If the reduction in blood flow is severe or remains untreated, permanent disability and even death can occur.  Mortality and morbidity due to vasospasm ranges1-2 from 14-36% of patients.  Patients are at highest risk for vasospasm between days 5 and 10 after SAH. Irritating blood by-products cause the walls of an artery to contract and spasm.3​

The Approach

The Minnetronix Cerebrospinal Fluid (CSF) Treatment Platform offers a tailored process for the treatment and return of CSF, called “Neurapheresis™”. Using Neurapheresis in post-SAH patients is intended to rapidly remove red blood cells from the CSF shortly after SAH securement. The removal of degrading red blood cells and their released inflammatory byproducts may be accomplished more efficiently with Neurapheresis than with standard gravity-dependent drains. It is theorized that early, rapid filtration of red blood cells post-SAH may reduce the incidence of cerebral vasospasm and thus may contribute to a shorter length of stay, less utilization of hospital resources, improved clinical functional outcomes, and an overall reduced healthcare economic burden.4

The Result

As part of Minnetronix’ strategy to identify and develop proprietary technologies intended to solve unmet clinical needs, the company is actively developing this platform. Minnetronix’ robust experience in the development of complex electromechanical medical devices makes it well-suited to pursue this unique solution to a difficult challenge. The company is also interested in exploring whether CSF treatment may have additional applications in other neurotoxic disease states.

If interested in the Minnetronix Cerebrospinal Fluid Treatment Platform, please contact us to discuss potential co-development or other partnering opportunities.

CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.

  1. US Brain Aneurysm Foundation, http://www.bafound.org/aneurysm-complications .
  2. Lindegaard K et al. Clinical course of spontaneous subarachnoid hemorrhage: a population based study in Kind County, Washington. Neurologi. 1993;43:712-718.
  3. http://www.mayfieldclinic.com/PE-SAH.HTM#.VgwwOk3luUk
  4. Bardutzky J et al. EARLYDRAIN- Outcome after Early Lumbar CSF-Drainage in Aneurysmal Subarachnoid Hemorrhage: Study Protocol for a Randomized Controlled Trial. Trials12 (2011):203.